Amycretin Just Crushed Semaglutide in a Weight Loss Meta-Analysis. Here Is What the Data Actually Show.

A drug you have probably never heard of just posted weight loss numbers that make semaglutide look like a warm-up exercise. In a network meta-analysis of six randomized trials enrolling 4,642 participants, high-dose subcutaneous amycretin produced a mean body weight reduction of 23.95 percent. Semaglutide 2.4 mg managed 11.45 percent in the same comparison. That is not an incremental improvement. That is a different category of result.

The study, published in Endocrinology, Diabetes & Metabolism in May 2026, ranks amycretin first among all amylin-based therapies tested for weight management in adults without diabetes. Behind it sits eloralintide at 18 percent and CagriSema at 17 percent. The findings suggest that the next wave of obesity drugs will not just be stronger GLP-1 agonists. They will be molecules that activate a second, complementary pathway that current blockbusters largely ignore.

What Are Amylin-Based Therapies?

Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells after a meal. It works alongside GLP-1 to regulate appetite and blood sugar, but through distinct neural circuits. Where GLP-1 receptor agonists primarily act on brainstem nuclei to suppress appetite and slow gastric emptying, amylin receptor agonists target the area postrema and nucleus tractus solitarius through a different receptor complex, the calcitonin receptor-based receptor (CTR).

The clinical rationale is straightforward: if GLP-1 agonists produce roughly 15 to 20 percent weight loss at their ceiling, adding amylin receptor activation could push past that ceiling by engaging a parallel satiety signal. This is the logic behind three distinct drug programs that are now delivering Phase 2 and Phase 3 data.

The Meta-Analysis: Head-to-Head Rankings

Kamrul-Hasan et al. conducted a frequentist random-effects network meta-analysis comparing novel amylin-based therapies against placebo and active comparators across six randomized controlled trials. The primary outcome was percent change in body weight from baseline. Here is how the agents ranked:

Amycretin (high-dose SC) — 23.95% mean weight reduction, P score 1.00

Eloralintide (high-dose) — 18.01%, P score 0.89

CagriSema (high-dose) — 17.18%, P score 0.85

Semaglutide 2.4 mg — 11.45%

Liraglutide 3.0 mg — 6.4%

The pattern held across secondary endpoints including absolute weight change, BMI reduction, waist circumference, and categorical weight-loss thresholds. Amycretin dominated every metric.

The trade-off was gastrointestinal side effects. Nausea, vomiting, and constipation were more common with high-dose amylin-based therapies, particularly oral amycretin and CagriSema. Diarrhea was more prevalent with semaglutide. Only high-dose CagriSema increased treatment discontinuation due to adverse events. The authors caution that the data remain sparse and low-certainty, and that larger trials are needed to confirm these rankings.

Amycretin: The Molecule Behind the Numbers

Amycretin is developed by Novo Nordisk and represents a genuinely novel pharmacological concept: a single unimolecular co-agonist that activates both the GLP-1 receptor and the amylin receptor simultaneously. This is not a fixed-dose combination like CagriSema (cagrilintide plus semaglutide). It is one molecule binding two receptor systems.

The Phase 1b/2a trial, published in The Lancet in July 2025, enrolled 125 participants with overweight or obesity at a single center in San Antonio, Texas. The results were striking:

60 mg once-weekly SC (Part B): 24.3% weight loss at week 36 vs. 1.1% placebo

20 mg SC (Part C): 22.0% at week 36 vs. 1.9% placebo

5 mg SC (Part D): 16.2% at week 28 vs. 2.3% placebo

1.25 mg SC (Part E): 9.7% at week 20 vs. 2.0% placebo

An oral formulation also showed promise: 13.1% weight loss at 12 weeks in a separate dose-escalation study. The oral version uses a tablet taken once daily, which could dramatically expand access compared to injectable therapies.

The safety profile was consistent with the GLP-1 and amylin agonist classes. Gastrointestinal events were the most common adverse effects, mostly mild to moderate and resolving by end of study. A high withdrawal rate was noted, though many discontinuations were for reasons unrelated to side effects.

Eloralintide: Lilly’s Pure Amylin Play

While amycretin targets both GLP-1 and amylin receptors in one molecule, Eli Lilly’s eloralintide takes a different approach. It is a selective, long-acting amylin receptor agonist designed for once-weekly subcutaneous injection. The idea is to pair it with existing GLP-1 agonists rather than build both activities into a single molecule.

The Phase 2 trial, published in The Lancet in December 2025, enrolled 263 participants across 46 US centers. At 48 weeks, the dose-response data were compelling:

9 mg once-weekly: 20% weight loss

6 mg: 18%

3 mg: 12%

1 mg: 9%

Placebo: 0.4%

A notable advantage of eloralintide was its gastrointestinal profile. Nausea rates were lower than typical GLP-1 agonists, and the Phase 1 proof-of-concept study (12 weeks, 100 participants) reported only 8% nausea and 4% vomiting. This could make eloralintide an attractive add-on for patients who cannot tolerate the GI side effects of high-dose GLP-1 drugs.

What This Means for the Weight Loss Landscape

The amylin meta-analysis signals a structural shift in obesity pharmacotherapy. The first generation of GLP-1 drugs (semaglutide, liraglutide) established that hormonal appetite suppression works. The second generation (tirzepatide, which adds GIP receptor activation) pushed efficacy higher. The amylin-based third generation targets a completely separate satiety pathway, which means the ceiling has not yet been reached.

Three practical implications stand out:

1. Combination potential: Amylin agonists can be layered on top of GLP-1 therapy. CagriSema (cagrilintide + semaglutide) already demonstrates this principle at 17% weight loss. As eloralintide data mature, expect trials pairing it with semaglutide or tirzepatide.

2. Oral formulation access: Amycretin’s oral version showed 13% weight loss in just 12 weeks. If Phase 3 confirms these numbers, an oral pill that rivals injectable semaglutide would be a massive access breakthrough. No needles, no cold chain, no specialty pharmacy.

3. Beyond weight loss: Amylin receptors are expressed in bone, cartilage, and the cardiovascular system. Early research suggests amylin agonists may have joint-protective and cardiovascular benefits that pure GLP-1 drugs do not offer. A June 2026 paper in the International Journal of Obesity specifically proposes dual amylin and calcitonin receptor agonists (DACRAs) as disease-modifying osteoarthritis drugs, arguing they could reduce weight, relieve pain, and preserve cartilage simultaneously.

The Oria Take

The peptide space keeps delivering surprises. Five years ago, 15 percent weight loss from a drug was considered remarkable. Now amycretin is posting 24 percent in early trials and the field is already asking whether 30 percent is achievable with the right combination.

For anyone tracking peptide therapy developments, the amylin pathway is where the action is moving. These are not distant pipeline fantasies. Amycretin is in Phase 2/3 trials. Eloralintide just completed a 263-person Phase 2 with clean 48-week data. CagriSema has Phase 3 results expected soon. The regulatory timeline suggests one or more of these agents could reach the market within two to three years.

The data also reinforces a principle that the peptide community has understood intuitively for years: single-target drugs hit ceilings, and multi-target approaches break through them. Whether that means stacking individual peptides or using designed multi-agonists like amycretin, the future of weight management is combination biology.

Evidence Grade: B+ — Strong emerging data from a network meta-analysis of 6 RCTs (N=4,642) and multiple Phase 1/2 trials published in The Lancet. Limited by small sample sizes in individual amycretin trials (N=125), low-certainty evidence per GRADE assessment, and absence of Phase 3 outcomes. The biological rationale is well-established and the effect sizes are consistent across studies.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Amycretin and eloralintide are investigational agents not yet approved by the FDA or any regulatory body. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Oria BioStack provides educational content about peptide science and does not sell or distribute investigational drugs.